Generics USA-based Hospira (NYSE: HSP), a global leader in injectable drugs and infusion technologies, reported results for the third quarter of 2012, with net sales rising1.8% to $994 million, and adjusted diluted earnings per share at $0.47, versus a net loss of $88.9 million, or $0.54 per share, in the 2011 quarter, and beating analysts' consensus expectations of $0.46. Diluted earnings per share on a Generally Accepted Accounting Principles (GAAP) basis were $0.01. 8 November 2012